Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sweet Remedy (tadalafil) gummy is a PDE5 inhibitor, small molecule drug. It is being evaluated in phase 1 clinical trials for the treatment of patients with erectile dysfunction.
Brand Name : Sweet Remedy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2023
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Seattle Gummy Company Secures The First (IND) Gummy Drug Approval From FDA
Details : SGC scientists have developed a suite of technologies that enable the incorporation of various drug compounds into a novel gummy matrix, thus solving drug solubility, stability, and taste issues.
Brand Name : Ceteric Allergy Gummy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2020
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?